[CHRS] Coherus BioSciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 28.05 Change: 0.05 (0.18%)
Ext. hours: Change: 0 (0%)

chart CHRS

Refresh chart

Strongest Trends Summary For CHRS

CHRS is in the medium-term up 31% above S&P in 2 months and up 68% in 6 months. In the long-term down -56% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -63.81% Sales Growth - Q/Q-10.52% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-50.75% ROE-203.75% ROI
Current Ratio2.77 Quick Ratio Long Term Debt/Equity Debt Ratio1.36
Gross Margin Operating Margin-245.92% Net Profit Margin-274.14% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-730 K Cash From Investing Activities-1.31 M Cash From Operating Activities-33.06 M Gross Profit
Net Profit-40.73 M Operating Profit-36.75 M Total Assets153.15 M Total Current Assets143.9 M
Total Current Liabilities51.91 M Total Debt Total Liabilities115 M Total Revenue5.81 M
Technical Data
High 52 week20.25 Low 52 week8.38 Last close18.55 Last change5.64%
RSI73.29 Average true range0.91 Beta1.63 Volume340.72 K
Simple moving average 20 days14.79% Simple moving average 50 days22.55% Simple moving average 200 days30.79%
Performance Data
Performance Week6.18% Performance Month25.85% Performance Quart33.07% Performance Half66.52%
Performance Year15.22% Performance Year-to-date104.97% Volatility daily2.86% Volatility weekly6.39%
Volatility monthly13.09% Volatility yearly45.35% Relative Volume232.26% Average Volume852.67 K
New High New Low

News

2019-06-21 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-06-14 17:59:55 | Hedge Funds Have Never Been This Bullish On Coherus Biosciences Inc CHRS

2019-06-11 08:06:09 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-06-10 08:07:02 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-06-06 08:05:34 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-06-04 08:03:49 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-05-23 10:38:02 | Amgen AMGN Offers to Acquire Drug Discovery Platform

2019-05-23 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-05-22 09:55:30 | Did Coherus BioSciences's NASDAQ:CHRS Share Price Deserve to Gain 29%?

2019-05-22 09:30:00 | Coherus BioSciences Management to Present at Jefferies 2019 Global Healthcare Conference

2019-05-21 09:04:52 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-05-13 11:30:00 | 2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan

2019-05-09 21:55:44 | Edited Transcript of CHRS earnings conference call or presentation 9-May-19 8:30pm GMT

2019-05-09 19:54:01 | Coherus BioSciences, Inc. CHRS Q1 2019 Earnings Call Transcript

2019-05-09 17:35:09 | Coherus BioSciences CHRS Reports Q1 Loss, Tops Revenue Estimates

2019-05-09 16:24:21 | Coherus BioSciences: 1Q Earnings Snapshot

2019-05-09 16:01:00 | Coherus BioSciences Reports Corporate Highlights and First Quarter 2019 Financial Results

2019-05-08 16:04:16 | Did Hedge Funds Drop The Ball On Coherus Biosciences Inc CHRS ?

2019-05-07 08:04:48 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-05-02 17:00:00 | Coherus BioSciences and Amgen Settle Trade Secrets Action

2019-05-02 09:30:00 | Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences

2019-04-30 08:04:32 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-04-26 06:58:10 | Moving Average Crossover Alert: Coherus BioSciences

2019-04-25 09:27:01 | The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

2019-04-24 09:11:01 | 5 Biotech Stocks Defying the Medicare-for-All Scare

2019-04-19 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-04-09 08:41:12 | Coherus CHRS Catches Eye: Stock Jumps 6.9%

2019-04-08 16:32:00 | Why Sony, AMC Entertainment Holdings, and Coherus BioSciences Jumped Today

2019-04-08 13:04:00 | Here's Why Coherus BioSciences Popped Today

2019-04-07 09:27:20 | Read This Before Buying Coherus BioSciences, Inc. NASDAQ:CHRS Shares

2019-04-05 16:00:00 | Coherus BioSciences Announces Unaudited First Quarter 2019 UDENYCA™ Net Sales

2019-04-05 08:30:00 | Coherus BioSciences to Report First Quarter Financial Results on May 9th

2019-03-28 09:30:00 | Coherus BioSciences Management to Present at H.C. Wainwright & Co. Global Life Sciences Conference

2019-03-22 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-03-19 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-03-19 08:32:35 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-03-18 09:30:00 | Coherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer

2019-03-12 10:30:08 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-03-05 08:30:00 | New Research: Key Drivers of Growth for American Tower Corporation REIT, Lowe's Companies, Mimecast, Live Nation Entertainment, Intercept Pharmaceuticals, and Coherus BioSciences — Factors of Influence, Major Initiatives and Sustained Production

2019-03-05 08:05:48 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-03-01 06:53:21 | Edited Transcript of CHRS earnings conference call or presentation 28-Feb-19 9:30pm GMT

2019-02-28 19:10:53 | Coherus BioSciences Inc CHRS Q4 2018 Earnings Conference Call Transcript

2019-02-28 16:30:00 | Coherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-26 09:30:00 | Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March

2019-02-22 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-02-14 09:30:00 | Coherus BioSciences to Report Fourth Quarter and Full Year 2018 Financial Results on February 28th

2019-02-11 14:46:00 | Here's Why Coherus BioSciences Rose 48.7% in January

2019-02-08 08:03:38 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-02-07 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-01-25 12:00:00 | Coherus BioSciences Announces Filing of Patent Infringement Suit Against Amgen Directed to Amgen’s Humira Biosimilar Formulation